1.Remission and remission-related factors in lupus nephritis patients: a cohort study
Yi YANG ; Ming KU ; Ran LUO ; Rui ZENG ; Shuwang GE ; Gang XU
Chinese Journal of Nephrology 2017;33(8):567-572
Objective To explore prognosis and remission-related factors in lupus nephritis (LN) patients.Methods Patients diagnosed as LN by renal biopsy in Tongji Hospital Affiliated to Tongji Medical College,Huazhong University of Science and Technology between Jan 1,2011 and July 31,2016 were enrolled.All related baseline clinical data was recorded and regular follow-up was performed.Kaplan-Meier curves was used to analyze partial remission and complete remission rates.Log-rank test was performed to compare remission rates of patients with nephrotic-range proteinuria (24-hour proteinuria≥3.5 g) and without nephrotic-range proteinuria (24-hour proteinuria<3.5 g).Univariate and muhivariate Cox regression analyses were performed to evaluate the remission-related factors in different periods.Results A total of 115 patients,with 88.7% female and (31.5±9.5)years mean age,were followed up for up to 5 years.During follow-up period 2 patients died and 1 dialyzed.The 6-,12-,24-and 36-and 48-month renal partial remission and complete remission rates were 33.3%,58.2%,71.5%,84.0%,89.6%,and 18.9%,40.5%,67.3%,79.4%,87.0%,respectively.Patients without nephrotic-range proteinuria had higher complete remission than patients with nephrotic -range proteinuria (HR=2.01,95%CI 1.15-3.34,P=0.014),but there was no difference in their partial remission (HR=1.33,95% CI 0.74-2.43,P=0.341).Multivariate Cox regression model indicated that every 1 g/L increase in baseline level of serum albumin was associated with increased 8% and 9% risk,respectively,in partial remission (HR=1.08,95%CI 1.01-1.15,P=0.024) and complete remission (HR=1.09,95%CI 1.01-1.07,P=0.038).Conclusions Around half of LN patients reach remission during 1 year.Patients without nephrotic-range proteinuria have higher complete remission,and serum albumin is a remission-related factors.
2.Large germline deletion of the VHL gene in Chinese families with von Hippel-Lindau syndrome.
Jin ZHANG ; Hai-ge CHEN ; Wei XUE ; Li-xin ZHOU ; Yi-ran HUANG
Chinese Journal of Medical Genetics 2009;26(5):539-541
OBJECTIVETo investigate the large germline deletion of the VHL gene in Chinese families with von Hippel-Lindau disease (VHL).
METHODSThe large deletion of the VHL gene in 20 unrelated Chinese VHL families was analyzed by using universal primer quantitative fluorescent multiplex polymerase chain reaction (UPQFM-PCR) and GeneScan analysis.
RESULTSPartial and complete VHL gene deletions were detected in 6 probands, including 3 exon 1 deletions, 1 exon 3 and 2 complete deletions. Of the 2 families with the complete deletions, patients developed multi-centric hemangioblastoma in the retina and central nervous system (CNS), and none developed renal cell carcinoma (RCC).
CONCLUSIONPartial and complete VHL gene deletions could be detected in Chinese kindreds with von Hippel-Lindau disease and the test for large deletion of the VHL gene should be implemented in routine DNA diagnosis for VHL disease. Further investigations are required to confirm that entire VHL deletions may be associated with a high risk of hemangioblastomas in the retina and central nervous system.
Asian Continental Ancestry Group ; genetics ; Exons ; Female ; Gene Deletion ; Germ-Line Mutation ; Humans ; Male ; Pedigree ; Von Hippel-Lindau Tumor Suppressor Protein ; genetics ; von Hippel-Lindau Disease ; genetics
3.pH and GSH dual-responsive silybin nano-micelles for inhibition of breast cancer activity and metastasis in vitro
Ling-yu JIA ; Dan-li HAO ; Jia-ying YANG ; Ran XIE ; Ge-jing DE ; Hong YI ; Chen ZANG ; Yu ZHAO ; Qing-he ZHAO ; Yan-jun CHEN
Acta Pharmaceutica Sinica 2023;58(9):2785-2793
The clinical tumor therapy was greatly challenged due to the complex characteristics of tumor microenvironment, however, which also provide arena for novel therapeutic strategies. In this study, poly(2-ethyl-2-oxazoline)-poly(lactic acid)-SS-poly(
5.Clinical trial of paliperidone extended-release tablets in the treatment of schizophrenia
Jin-Cheng WANG ; Chao-Min WANG ; Yi-Ran GE ; Hong GUO ; Bo XIN ; Xiao-Chuan ZHAO ; Mei SONG
The Chinese Journal of Clinical Pharmacology 2018;34(7):786-789
Objective To observe the clinical efficacy and safety of paliperidone extended-release tablets in the treatment of schizophrenia.Methods Thirty patients with schizophrenia were randomly divided into control group and treatment group with 15 cases per group.Control group was given olanzapine with the initial dose of 10 mg and the maximum dose of 20 mg,bid,orally.Treatment group was given paliperidone sustained-release tablets 3 mg,qd,orally,and according to the patients' symptoms,the dose was increased at the speed of 3 mg · d-1,also the maximum dose was 12 mg.Two groups were treated for 8 weeks.The clinical efficacy,myocardial enzymes,executive function and adverse drug reactions were compared between the two groups.Results After treatment,the total effective rates of the treatment and control groups were 93.33% (14 cases/15 cases) and (9 cases/15 cases) with significant difference (P < 0.05).After treatment,the main indexes in treatment and control groups were compared:alkaline phosphatase were (72.51 ±8.82) and (83.24 ±9.15) U · L-1,alpha hydroxybutyrate dehydrogenase were (128.66 ± 15.42) and (142.13 ± 12.65) U · L-1,creatine kinase were (56.37 ± 8.29) and (62.15 ± 6.45) mmol L-1,lactate dehydrogenase were (51.35 ± 6.37) and (58.32 ± 6.15) mmol · L-1,creatine kinase isoenzyme were (4.15 ± 2.40) and (5.86 ± 0.87) mmol · L-1,wisconsin card sorting test persistent error number were (6.13 ± 0.85) and (5.08 ± 0.68) times,executive function behavior rating scale scores were (66.82 ± 8.46) and (55.68 ± 6.24) points,the differences were statistically significant (all P < 0.05).No adverse drug reactions occurred in the two groups.Conclusion Paliperidone extended-release tablets have a definitive clinical efficacy and safety in the treatment of schizophrenia,which can significantly improve the myocardial function and executive function.
6.Preparation of docetaxel-loaded nanomicelles and their anti-Lewis lung cancer effect in vitro.
Ya-Jie WANG ; Jie WANG ; Dan-Li HAO ; Qiao-Xin YUE ; Ran XIE ; Ge-Jing DE ; Hong YI ; Chen ZANG ; Qing-He ZHAO ; Yan-Jun CHEN
China Journal of Chinese Materia Medica 2019;44(11):2251-2259
Docetaxel-loaded nanomicelles were prepared in this study to improve the solubility and tumor targeting effect of docetaxel(DTX),and further evaluate their anticancer effects in vitro. PBAE-DTX nanomicelles were prepared by film-hydration method with amphiphilic block copolymer polyethyleneglycol methoxy-polylactide(PELA) and pH sensitive triblock copolymer polyethyleneglycol methoxy-polylactide-poly-β-aminoester(PBAE) were used respectively to prepare PELA-DTX nanomicelles and PBAE-DTX nanomicelles. The nanomicelles were characterized by physicochemical properties and the activity of mice Lewis lung cancer cells was studied. The results of particle size measurement showed that the blank micelles and drug-loaded micelles had similar particle sizes, ranging from 10 to 100 nm. The particle size of PBAE micelles was changed under weak acidic conditions, with good pH response. The encapsulation efficiency of the above two types of DTX-loaded nanomicelles determined by HPLC was(93.8±1.70)% and(87.2±4.10)%, and the drug loading amount was(5.3±0.10)% and(4.9±0.05)%,respectively. Furthermore,the DTX micelles also showed significant inhibitory effects on Lewis lung cancer cells by MTT assay, and pH-sensitive PBAE-DTX showed better cytotoxicity. The results of flow cytometry indicated that,the apoptosis rate of lung cancer Lewis cells was(20.72±1.47)%,(29.71±2.38)%,and(40.91±1.90)%(P<0.05) at 48 h after treatment in DTX,PELA-DTX,and PBAE-DTX groups. The results showed that different docetaxel preparations could promote the apoptosis of Lewis cells, and PBAE-DTX had stronger apoptotic-promoting effect. The pH-sensitive DTX-loaded micelles are promising candidates in developing stimuli triggered drug delivery systems in acidic tumor micro-environments with improved inhibitory effects of tumor growth on Lewis lung cancer.
Animals
;
Antineoplastic Agents
;
pharmacology
;
Cell Line, Tumor
;
Docetaxel
;
pharmacology
;
Drug Carriers
;
Lung Neoplasms
;
drug therapy
;
pathology
;
Mice
;
Micelles
;
Nanoparticles
;
Particle Size
;
Taxoids
7. Protectivity of hepatitis B surface antibody in children between 1 and 3 years after successful blocking of mother-to-child transmission
Weihua CAO ; Ying ZHNAG ; Minghui LI ; Chongping RAN ; Tianlin QI ; Xingyue WANG ; Yuhong HU ; Mingshu ZHOU ; Lu ZHANG ; Yao LU ; Shuling WU ; Ge SHEN ; Hongxiao HAO ; Min CHANG ; Leiping HU ; Ruyu LIU ; Wenhao HUA ; Wei YI ; Yao XIE
Chinese Journal of Experimental and Clinical Virology 2017;31(5):401-404
Objective:
To investigate the change of hepatitis B surface antibody (HBsAb) titer and its long-term protection and infection rates between 1 and 3-year-old children whose mothers were chronic hepatitis B pregnant woman with HBeAg positive and high viral load after successful blocking of mother-to-child transmission.
Methods:
One-year-old children whose mothers were hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive, with HBV DNA≥106IU/ml were enrolled, then were followed up till 3 years old, and tested the five serological markers of hepatitis B and biochemical parameters at the age of one and three years respectively, and analyzed HBsAb titer, positive rate, negative rate and infection rate of 1 to 3-year-old children without enhanced vaccination; meanwhile, data of HBsAb titers at the age of 7 months were collected HBsAb titer, positive rate, and negative rate were analyzed.
Results:
Totally 264 1-year-old children were enrolled into the study, including 178 children without enhanced vaccination between seven months and 1 year of age, and 114 children without enhanced vaccination between 1 year and 3 years of age. Our result showed that there were no infected children at the age between 1 and 3 years. HBsAb titer decreased from 7 months to 1 year old and dropped from 1 000 IU/L to 509.43 IU/L (